Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Castle Biosciences ( (CSTL) ) has provided an update.
Castle Biosciences reported strong financial results for the third quarter of 2025, with revenue reaching $83 million and a significant increase in test report volumes for their core products. Despite challenges such as the Novitas LCD and discontinuation of IDgenetix, the company raised its full-year revenue guidance to $327-335 million. The launch of AdvanceAD-Tx, a new test for atopic dermatitis, highlights their commitment to addressing unmet needs in clinical dermatology.
The most recent analyst rating on (CSTL) stock is a Buy with a $23.56 price target. To see the full list of analyst forecasts on Castle Biosciences stock, see the CSTL Stock Forecast page.
Spark’s Take on CSTL Stock
According to Spark, TipRanks’ AI Analyst, CSTL is a Neutral.
Castle Biosciences’ overall stock score reflects a mixed outlook. The most significant factor is the company’s financial performance, which shows operational challenges and negative profitability. Technical analysis indicates strong momentum, but valuation concerns persist due to ongoing losses. The earnings call provided a positive outlook with raised revenue guidance and strategic progress, balancing some of the financial weaknesses.
To see Spark’s full report on CSTL stock, click here.
More about Castle Biosciences
Castle Biosciences is a company focused on improving health through innovative diagnostic tests that guide patient care, primarily in the dermatologic and gastrointestinal sectors. Their core products include DecisionDx-Melanoma and TissueCypher, which are pivotal in their market offerings.
Average Trading Volume: 452,120
Technical Sentiment Signal: Buy
Current Market Cap: $739.7M
For detailed information about CSTL stock, go to TipRanks’ Stock Analysis page.